Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …

An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which
results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously …

Stimulus-cleavable nanoscale drug delivery systems are receiving significant attention
owing to their capability of achieving exquisite control over drug release via the exposure to …

Combining the selective targeting of tumor cells through antigen-directed recognition and
potent cell-killing by cytotoxic payloads, antibody-drug conjugates (ADCs) have emerged in …

The antibody–drug conjugate (ADC) field has undergone a renaissance, with substantial
recent developmental investment and subsequent drug approvals over the past 6 years. In …

Antibody–drug conjugates (ADC) using DNA topoisomerase I inhibitor DXd/SN-38 have
transformed cancer treatment, yet more effective ADCs are needed for overcoming …

Cathepsin B is a lysosomal cysteine protease, contributing to vital cellular homeostatic
processes including protein turnover, macroautophagy of damaged organelles, antigen …

Bioorthogonal click chemistry—employing antibody-conjugated trans-cyclooctenes (TCO)
and tetrazine (Tz)-based radioligands able to covalently bind in vivo—appeared recently as …

We herein report the development and evaluation of a novel HER2-targeting antibody–drug
conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our …